following a full submission assessed under the end of life and ultra-orphan medicine process:
liposomal formulation of daunorubicin/cytarabine (Vyxeos®) is accepted for use within NHSScotland.
Indication under review: The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes.In a randomised phase III study, in adults (aged 60 to 75 years) with high risk AML, liposomal daunorubicin/cytarabine improved overall survival when compared with a standard of care regimen.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of liposomal daunorubicin/cytarabine. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
- Medicine name:
- liposomal formulation of daunorubicin & cytarabine (Vyxeos)
- SMC ID:
Treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AMC-MRC)
- Pharmaceutical company
- Jazz Pharmaceuticals
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 11 March 2019